BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...

In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The FDA has approved BridgeBio Pharma's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.

In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other best mid cap biotech stocks to buy. On March 6, Jared Holz, Mizuho health care ...

Japan approved BridgeBio’s acoramidis (Beyonttra) for ATTR-CM, with AstraZeneca’s Alexion handling commercialization. BridgeBio will receive a $30 million milestone payment and low double ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO), a biotechnology company with a market capitalization of $6.2 billion focused on developing ...